Combination therapy for the treatment-of lower urinary tract symptoms

[0028]In one aspect the invention is directed to a pharmaceutical composition for the treatment of lower urinary tract symptoms (LUTS), especially LUTS which results from benign prostatic hypertrophy (BPH), comprising a beta 3 agonist selected from[0029]N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(3-cyclopentylpropyl)-5-tetrazolon-1-yl]benzenesulfonamide; and[0030]2N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide and[0031]a pharmaceutically acceptable carrier, and optionally a 5-alpha reductase inhibitor, or an NK-1 antagonist or an alpha-1 adrenergic antagonist or an anti-muscarinic agent.

[0032]These compounds are discussed and may be prepared as disclosed in U.S. Pat. No. 5,561,142 and U.S. Pat. No. 6,011,048, which are hereby incorporated by reference. A beta 3 agonist of the invention has been studied in postmenopausal women with OAB and has been found to improve micturition frequenc